Bone Formation in a Rat Tibial Defect Model Using Carboxymethyl Cellulose/BioC/Bone Morphogenic Protein-2 Hybrid Materials

• Published in: BioMed research international Vol. 2014; no. 2014; pp. 1 - 8
• Main Authors: Kim, Hak-Jun, Song, Sang-Heon, Song, Hae-Ryong, Kim, Sung Eun, Park, Kyeongsoon, Yun, Young-Pil
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01.01.2014; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Animals; Bone Morphogenetic Protein 2 - chemistry; Bone Morphogenetic Protein 2 - pharmacology; Bone Regeneration - drug effects; Bone Substitutes - chemistry; Bone Substitutes - pharmacology; Bone surgery; Calcium Phosphates - chemistry; Calcium Phosphates - pharmacology; Carboxymethylcellulose Sodium - chemistry; Carboxymethylcellulose Sodium - pharmacology; Cellulose; Defects; Disease Models, Animal; Hydrogels; Hydroxyapatite; Osteogenesis - drug effects; Rats; Rats, Sprague-Dawley; Studies; Surgery; Tibia - diagnostic imaging; Tibia - injuries; X-Ray Microtomography
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2014/230152

The objective of this study was to assess whether carboxymethyl cellulose- (CMC-) based hydrogel containing BioC (biphasic calcium phosphate (BCP); tricalcium phosphate (TCP) : hydroxyapatite (Hap) = 70 : 30) and bone morphogenic protein-2 (BMP-2) led to greater bone formation than CMC-based hydrogel containing BioC without BMP-2. In order to demonstrate bone formation at 4 and 8 weeks, plain radiographs, microcomputed tomography (micro-CT) evaluation, and histological studies were performed after implantation of all hybrid materials on an 8 mm defect of the right tibia in rats. The plain radiographs and micro-CT analyses revealed that CMC/BioC/BMP-2 (0.5 mg) led to much greater mineralization at 4 and 8 weeks than did CMC/BioC or CMC/Bio/BMP-2 (0.1 mg). Likewise, bone formation and bone remodeling studies revealed that CMC/BioC/BMP-2 (0.5 mg) led to a significantly greater amount of bone formation and bone remodeling at 4 and 8 weeks than did CMC/BioC or CMC/BioC/BMP-2 (0.1 mg). Histological studies revealed that mineralized bone tissue was present around the whole circumference of the defect site with CMC/BioC/BMP-2 (0.5 mg) but not with CMC/BioC or CMC/BioC/BMP-2 (0.1 mg) at 4 and 8 weeks. These results suggest that CMC/BioC/BMP-2 hybrid materials induced greater bone formation than CMC/BioC hybrid materials. Thus, CMC/BioC/BMP-2 hybrid materials may be used as an injectable substrate to regenerate bone defects.